In This Article:
Guggenheim lowered the firm’s price target on Merus (MRUS) to $109 from $111 and keeps a Buy rating on the shares after the company announced an exclusive agreement with privately-held Partner Therapeutics to exclusively licensed to PTx the right to commercialize zenocutuzumab for the treatment of NRG1 fusion-positive cancer in the U.S. The firm is updating its model to account for the license agreement, the analyst tells investors.
Don't Miss our Black Friday Offers:
-
Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
-
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRUS: